The new factory will enable the manufacture of both new and current medications and will be located at its current location in Cruiserath, Dublin 15.
The business claimed that it would be the first sterile drug product production plant for biologics in Europe.
Padraig Keane, Vice President of Cruiserath Biologics, stated, “This is significant news and a proud day at Cruiserath Biologics as this SDP facility strengthens not only our capabilities on campus but also allows us to be agile and responsive to patient needs across the globe.”
“This investment will expand our capacity for aseptic drug products, reinforce stable production for global supply and accelerate the development and commercialization of innovative biologic therapies alongside other pipeline medicines.”
Being among the earliest pharmaceutical firms to operate in Ireland, Bristol Myers Squibb has been a part of the country for 60 years.
More than 1,000 people will be employed at this location thanks to the new building.
The business anticipates finishing the design process and starting construction in March.
The facility is expected to begin operations in 2026.
“Bristol Myer Squibb’s decision to invest $400m at their Cruiserath campus along with 350 new jobs is most welcome news and underscores the strategic importance of Ireland in their global operations,” stated Michael Lohan, CEO of IDA Ireland.
“It demonstrates the company’s enduring dedication to Ireland and underscores the country’s appeal as a biopharma investment destination.”
The new facility will expand BMS’s current biologic production capabilities for pharmaceutical ingredients in bulk.
According to the company, the facility will enable the site’s production of sterile medicinal products by bringing in innovative technology and capabilities.
Ireland serves as BMS’s worldwide headquarters for External Manufacturing, and the company’s European Treasury Centre, commercial operations, and market supply operations team are all housed on the Blanchardstown site.
In Shannon, County Clare, the multinational also has a distribution hub.
A $1 billion investment was made in the biologic’s campus in 2016.